Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · Real-Time Price · USD
3.150
-0.010 (-0.32%)
At close: Jun 27, 2025, 4:00 PM
3.200
+0.050 (1.59%)
After-hours: Jun 27, 2025, 7:15 PM EDT
Cardiff Oncology Employees
As of December 31, 2024, Cardiff Oncology had 33 total employees, including 32 full-time and 1 part-time employees. The number of employees increased by 1 or 3.13% compared to the previous year.
Employees
33
Change (1Y)
1
Growth (1Y)
3.13%
Revenue / Employee
$17,788
Profits / Employee
-$1,481,152
Market Cap
209.56M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CRDF News
- 1 day ago - Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity - Seeking Alpha
- 10 days ago - Cardiff Oncology Names Roger Sidhu as Medical Chief - Market Watch
- 10 days ago - Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC - GlobeNewsWire
- 25 days ago - Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025 - GlobeNewsWire
- 6 weeks ago - Cardiff Oncology: Buying The First-Line Onvansertib Strategy - Seeking Alpha
- 7 weeks ago - Cardiff Oncology Reports First Quarter 2025 Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Cardiff Oncology: Expecting Massive Updates In Colon Cancer Soon - Seeking Alpha
- 2 months ago - Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients - GlobeNewsWire